Lutathera 370 MBq/mL solution for infusion, LysaKare 25 g/25 g solution for infusion clinical trials

A Phase I Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTA0-Tyr3-Octreotate in Children with Refractory or Recurrent Neuroblastoma expressing somatostatin receptors

This study is looking at a new treatment called Lutathera for children with a type of cancer called neuroblastoma that has come back or not responded to other treatments. The main goal is to find the safest dose of this new medicine for these children.